Clinical Trials
40
Active:0
Completed:14
Trial Phases
5 Phases
Phase 1:16
Phase 2:7
Phase 3:10
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 1
16 (44.4%)Phase 3
10 (27.8%)Phase 2
7 (19.4%)Not Applicable
2 (5.6%)Phase 4
1 (2.8%)Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Preparation for Infusion.
Not Applicable
Not yet recruiting
- Conditions
- Safety and Pharmacokinetics
- Interventions
- Drug: ¼ of the full (target) dose (solution, 5 ml)Drug: ½ of the full (target) dose (solution, 10 ml)Drug: full dose (solution, 20 ml)Drug: 1 ½ of the full (target) dose (solution, 30 ml)Drug: 2 full doses (solution, 40 ml)Drug: course administration of the selected doseOther: Placebo
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 70
- Registration Number
- NCT07184606
"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".
Not Applicable
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Drug: 1/10 therapeutic doseDrug: 1/2 therapeutic doseDrug: Patients with a verified diagnosis of COVID-19Drug: full therapeutic dose
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 35
- Registration Number
- NCT07156864
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
Phase 3
Not yet recruiting
- Conditions
- P. AeruginosaBaumanniiKlebsiella PneumoniaE.coli InfectionsEnterococcus Faecalis InfectionChronic Bacterial Cystitis
- Interventions
- Drug: Fluorothiazinone, tablets 300 mg
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 280
- Registration Number
- NCT06815549
Study of the Drug B11-FC (Botulism Treatment)
Phase 1
Not yet recruiting
- Conditions
- Botulism
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 40
- Registration Number
- NCT06580236
The Surveillance Clinical Study of Rickettsiosis
Recruiting
- Conditions
- Rickettsiosis
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Target Recruit Count
- 100
- Registration Number
- NCT06162975
- Locations
- 🇷🇺
Altai Republic Center for HIV prophylaxis and treatment, Gorno-Altaïsk, Altai Republic, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found